[Results of a multicentre double-blind randomised placebo-controlled clinical trial evaluating the efficacy and safety of Mexidol in the treatment of Attention Deficit Hyperactivity Disorder in Children (MEGA)].
Nikolay N ZavadenkoN Yu SuvorinovaT T BatyshevaO V BykovaA N PlatonovaD D GaynetdinovaE V LevitinaV V MashinI N VakulaN E MaximovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
The regimen of Mexidol, 125 mg film-coated tablets twice daily has been shown to be superior to the regimen of Mexidol, 125 mg film-coated tablets once daily and placebo. The safety profiles of the studied dosing regimens of Mexidol and placebo were comparable.